Seven-year MedCap Capital Holdings Ponzi case is over

With bankruptcy case concluded, investors stand to recover $400 million.
NOV 01, 2016
The seven-year unwinding of the billion-dollar Medical Capital Holdings Ponzi scheme is over, with swindled investors receiving more than $400 million. Last Friday in U.S. District Court, Central District of California, Judge David O. Carter issued his final judgment in the case, which began in July 2009 when the Securities and Exchange Commission sued Medical Capital for fraud. That lawsuit proved to be the death knell for dozens of small and mid-sized independent broker-dealers that sold the Medical Capital private placements and other private deals that soured. Swamped by the cost of investor complaints, many of the firms that sold the private placements closed. Mr. Carter ordered that Medical Capital Holdings and other related companies and executives pay disgorgement of $831 million. According to court documents, close to 9,000 Medical Capital investors were owed approximately $1.08 billion, while the cash on hand at the company was $2.9 million. Investors have recovered $432 million, according to the court appointed receiver, Thomas Seaman. That includes $151 million recovered and distributed by the receiver; $180 million from the bond indenture trustees, or banks; and $101 million from broker-dealers. Harmed MedCap investors received about 40 cents on the dollar, according to those figures. Investors in Ponzi schemes historically have gotten back far less, or five to 10 cents on the dollar. From 2003 to 2009, Medical Capital raised almost $2 billion through a network of independent broker-dealers, purportedly to buy discounted medical receivables such as unpaid doctor or hospital bills that Medical Capital would then collect at full price.

Latest News

The 2025 InvestmentNews Awards Excellence Awardees revealed
The 2025 InvestmentNews Awards Excellence Awardees revealed

From outstanding individuals to innovative organizations, find out who made the final shortlist for top honors at the IN awards, now in its second year.

Top RIA Cresset warns of 'inevitable' recession amid tariff uncertainty
Top RIA Cresset warns of 'inevitable' recession amid tariff uncertainty

Cresset's Susie Cranston is expecting an economic recession, but says her $65 billion RIA sees "great opportunity" to keep investing in a down market.

Edward Jones joins the crowd to sell more alternative investments
Edward Jones joins the crowd to sell more alternative investments

“There’s a big pull to alternative investments right now because of volatility of the stock market,” Kevin Gannon, CEO of Robert A. Stanger & Co., said.

Record RIA M&A activity marks strong start to 2025
Record RIA M&A activity marks strong start to 2025

Sellers shift focus: It's not about succession anymore.

IB+ Data Hub offers strategic edge for U.S. wealth advisors and RIAs advising business clients
IB+ Data Hub offers strategic edge for U.S. wealth advisors and RIAs advising business clients

Platform being adopted by independent-minded advisors who see insurance as a core pillar of their business.

SPONSORED Compliance in real time: Technology's expanding role in RIA oversight

RIAs face rising regulatory pressure in 2025. Forward-looking firms are responding with embedded technology, not more paperwork.

SPONSORED Advisory firms confront crossroads amid historic wealth transfer

As inheritances are set to reshape client portfolios and next-gen heirs demand digital-first experiences, firms are retooling their wealth tech stacks and succession models in real time.